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Clinical Data Collection in the Molecular Era
Evidenced-based medicine has been revolutionized by molecular biology, allowing for the development of deeper questions, more 
refined hypotheses, detailed diagnostics, targeted cellular processes, and more comprehensive data analyses. Yet, we have only 
begun to scratch the surface of how biomarkers and cellular activity affect diagnosis, treatment, and outcomes in most disease 
states. What we know about clinical data tied to molecular signatures comes through varying research methods. Data originates from
interventional or real-world sources through a specific trial or data collection effort. Each are equipped to address specific sets of 
questions with associated strengths and weaknesses. 
Clinical Data Collection Methods (Non-master Protocols)
The addition of molecular testing has provided more detail related to diagnosis, prognosis, and treatment of patients. However, it has
not dramatically altered most trial designs. Interventional trials generally focus on determining how patients with a given biomarker 
identified by a specified test respond to a particular drug (i.e., one test, one biomarker, one treatment). Observational or chart review
efforts can be used to identify potential molecularly based testing or treatment strategies but generally do not focus on a specific 
type of testing and rarely lead to a change in standard of care. 
Interventional Master Protocols (Umbrella, Basket and Platform) 
Master protocols address some of the challenges introduced by molecular medicine. Through shared infrastructure and screening 
methods, a more efficient data collection method is created. Like other interventional trials, the interventional master protocols 
generally focus on a specific treatment tied to a specific biomarker but have multiple adaptable arms (or disease histologies) running 
in a parallel fashion. (i.e., one or more tests with each linked to an associated biomarker, treatment, and study arm)
Real-world Master Observational Protocols
The master observational trial (MOT) is a new construct to bridge the gap that exists between the specificity of the interventional 
trials, and the broad nature of the actual practice of medicine. By hybridizing the scientific methods of the interventional trials with 
restricting data collection to the most clinically relevant elements, broader data collection can take place. Precise classification of 
molecular testing tied to longer-term outcomes across broad study populations allows for evaluation of higher complexity care 
models. The versatility of the MOT trial type allows for easy synergy with other trials and provides the flexibility of adding new 
elements or arms to address specific questions.
Pros and Cons
The quality of data tends to be proportional to the cost and complexity of collecting it. Investigational trials are the gold standard of 
evidence generation methods but are usually only used for drug development at only one point in time in a patients’ treatment 
history. Real-world data efforts allow for much broader exploration, but the many drugs in many patients harboring many biomarkers 
approach can make finding an unbiased benefit challenging. Theoretically, questions regarding benefits of continually advancing 
molecular testing, of treating rare alterations or combinations of alterations, of sequencing or combining treatments, and of using 
treatments not approved by the FDA or specialty societies can be answered using real-world data sets. However, these answers 
require data of sufficient quality and quantity to mitigate bias. Lack of patient consent limits ability to reach back to a specific patient 
to verify benefits. In all trials of molecular medicine, interventional or real-world, there needs to be enough patients screened and 
enrolled to identify rare or complex associations and benefits.
Nuances and Linking of Methods
Table 1 shows the differences between typical trial types. Individual trials may employ additional methods to increase the quality 
and reliability of data. Any of these trial types can be used in parallel or sequence with other trial types, providing the ability to 
collect more robust information. 
Challenges
We are beginning to understand the clinical implication of the foundational layer of molecular medicine: genomics. The deeper layers 
of transcriptomics, proteomics, metabolomics, epigenomics, cellular metabolism, microenvironment, host factors, immune factors, 
gut biome, and other factors steadily increase the complexity of clinical data collection. Ideally, we need to use every data collection 
method available to aggregate information on exponentially greater numbers of patients in order to truly understand personalized 
medicine. 
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